Echocardiography in Massachusetts

Ontact Health Co., Ltd. develops SONIX Health, an FDA-cleared (510(k) K240645) AI-powered echocardiography analysis workstation designed to automate cardiac ultrasound interpretation and measurement. The solution performs fully automated analysis of 81 diagnostic parameters with 98% image recognition accuracy and 91% measurement accuracy, eliminating the need for ECG input by automatically detecting heart cycles via valve motion analysis. SONIX Health operates as vendor-neutral software compatible with multi-vendor echocardiography equipment, deployable on-premise or cloud-based without requiring high-specification hardware. The platform streamlines workflow through one-touch analysis from imaging to report generation, reducing clinician workload and examination wait times while supporting training applications. The company emphasizes clinical validation through peer-reviewed publications in cardiovascular imaging journals and demonstrated deployment in hospital environments across multiple geographies. Target markets include cardiac diagnostic centers, hospital ultrasound departments, and training programs seeking to standardize and accelerate echocardiographic assessment.

Revvity, Inc. is a comprehensive life science solutions provider serving academia, pharmaceutical, biotech, clinical laboratories, contract research organizations, and healthcare professionals globally. The company operates across the drug discovery-to-diagnostics continuum, delivering integrated workflows in translational multi-omics, biomarker identification, imaging, screening, detection, diagnosis, and informatics. Product portfolio includes high-content screening instruments (Opera Phenix, EnVision plate readers), optical imaging systems (IVIS), cell analysis instruments (Cellometer), sample preparation equipment (Omni Bead Ruptor Elite homogenizers), and laboratory automation (Fontus workstations, LabChip systems). Reagent brands encompass BioLegend antibodies and flow cytometry reagents, AlphaLISA and SureFire immunoassays, HTRF TR-FRET assays, Dharmacon RNAi and CRISPR tools, and custom oligonucleotide synthesis. Representative diagnostic and clinical service offerings include newborn screening (33M+ annual screens), immunodiagnostics via EUROIMMUN solutions (85M+ blood samples analyzed), infectious disease serology, TB testing (T-SPOT.TB, 20M+ tested since 2002), reproductive health solutions (maternal/prenatal testing, cell-free DNA analysis, preeclampsia management), and clinical genomics services (300M+ tests performed). Licensing portfolio covers gene expression, editing, and viral vector technologies including LentiBOOST and Pin-point base editing platforms. Revvity serves 94% of top 50 global pharma companies, maintains ~11,000 employees worldwide, and operates on-site manufacturing, viral vector engineering, preclinical oncology services, and clinical testing. Regulatory presence includes FDA and CE approvals across diagnostics and instruments. The company integrates acquisition-driven growth with organic R&D, supporting discovery through clinical deployment across life science workflows.

Oncovision is a Spanish-based medical imaging company specializing in innovative diagnostic and therapeutic imaging devices for oncology, radiology, surgery, and nuclear medicine. The company develops molecular imaging solutions focused on early cancer detection and treatment planning. Primary product lines include Mammi (breast PET imaging system for breast cancer diagnosis), Sentinella (intraoperative imaging system for surgical guidance), WProbe (portable probe device for accurate, practical imaging applications), and CaremiBrain (neuroimaging application for Alzheimer's disease diagnosis). The company serves surgeons, radiologists, oncologists, and nuclear physicians. Oncovision holds recognition as an innovative SME (PYME INNOVADORA) with validity through May 2027, indicating compliance with Spanish innovation standards. The company has received funding through Generalitat Valenciana's Fondos Plan Resistir Plus and is capitalized by Innvierte, an investment initiative of Spain's CDTI (Centro para el Desarrollo Tecnológico Industrial). The organization emphasizes innovation, commitment, excellence, and continuous improvement in molecular imaging technology for cancer diagnosis and treatment.

Harvard Bioscience Inc is a holding company and distributor of laboratory and research equipment serving academic institutions, contract research organizations (CROs), pharmaceutical, and biotech companies. The company operates through multiple subsidiary brands including Data Sciences International (DSI), BTX Electroporation Systems, Multi Channel Systems (MCS), Biochrom, HEKA, Harvard Apparatus, Panlab, Warner Instruments, CMA Microdialysis, and Hugo Sachs Elektronik. Product portfolio encompasses electrophysiology systems (patch clamp amplifiers, multielectrode arrays, Ussing chambers), spectrophotometers and colorimeters (Ultrospec series, Biowave), amino acid analyzers, telemetry and behavioral monitoring systems, electroporation devices, and isolated organ perfusion systems. The company serves discovery, production, and regulatory compliance workflows for life-saving therapeutic development. Products include the INCUB8 multiwell MEA system for optical and electrophysiological recording, HEKA EPC 10 USB 3.0 patch clamp amplifier, IntraCell laser-based optoporation system, VivaMARS activity monitoring platform, Ponemah software (GLP and 21 CFR Part 11 compliant), continuous glucose telemetry for rodents, and various UV-Vis spectrophotometric instruments. The company actively participates in major scientific conferences including SfN, APS, ECS, and ISSCR, and maintains active engagement in neuroscience, cardiac, and translational research communities.

UltraSight is an Israeli digital health company specializing in AI-powered cardiac ultrasound imaging software. The platform provides real-time guidance and quality assessment to enable healthcare professionals of any sonography proficiency level to consistently perform high-quality cardiac ultrasound acquisitions at the point of care—in clinics, community hospitals, ambulances, and remote/rural areas. The software integrates with ultrasound devices (including Philips Lumify) and complies with healthcare standards (HL7, DICOM). UltraSight has achieved FDA clearance and CE Mark certification. The solution addresses critical clinical needs in emergency medicine, out-of-hospital care, critical care monitoring, and resource-limited settings, democratizing access to cardiac imaging while improving diagnostic accuracy and reducing repeat procedures. Clinical evidence demonstrates that novice users achieve diagnostic-quality images approaching expert sonographer performance following minimal training.